

# Pharmacotherapy for Venous Thromboprophylaxis following Total Hip or Knee Arthroplasty: A Systematic Review and Network Meta-analysis

Bryan Song Jun Yong<sup>1,\*</sup> Ryan Ruiyang Ling, MBBS<sup>2,\*</sup> Ruiqi Li<sup>1</sup> Jane Wenjin Poh<sup>1</sup>  
 Chuen Seng Tan, PhD<sup>3</sup> Sean Wei Loong Ho, FRCS<sup>1,2,4</sup> Bram Rochweg, MD, MSc<sup>5,6</sup>  
 Roopen Arya, PhD<sup>7</sup> Kollengode Ramanathan, FCICM<sup>2,8,†</sup> Bingwen Eugene Fan, MRCP<sup>1,2,9,†</sup>

<sup>1</sup> Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore

<sup>2</sup> Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore, Singapore

<sup>3</sup> Saw Swee Hock School of Public Health, National University of Singapore, National University Health System, Singapore, Singapore

<sup>4</sup> Department of Orthopaedic Surgery, Tan Tock Seng Hospital, Singapore, Singapore

<sup>5</sup> Division of Critical Care, Department of Medicine, McMaster University, Hamilton, Ontario, Canada

<sup>6</sup> Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada

**Address for correspondence** Bingwen Eugene Fan, MRCP, Department of Haematology, Tan Tock Seng Hospital, Singapore, Singapore (e-mail: Bingwen\_Eugene\_Fan@ttsh.com.sg).

<sup>7</sup> Department of Haematological Medicine, King's Thrombosis Centre, King's College Hospital Foundation NHS Trust, London, United Kingdom

<sup>8</sup> Cardiothoracic Intensive Care Unit, National University Heart Centre, National University Hospital, Singapore, Singapore

<sup>9</sup> Department of Haematology, Tan Tock Seng Hospital, Singapore, Singapore

Semin Thromb Hemost

## Abstract

The optimal pharmacological prophylaxis for venous thromboembolism (VTE) after hip or knee arthroplasty is uncertain. We conducted a systematic review and network meta-analysis to compare the efficacy and safety of various medications. We searched multiple databases for randomized clinical trials (RCTs) comparing medications (including factor Xa inhibitors, factor IIa inhibitor, warfarin, unfractionated heparin [UFH], low-molecular-weight heparin [LMWH], aspirin, pentasaccharide) for VTE prophylaxis post-arthroplasty. Outcomes included any postoperative VTE identified with screening, major bleeding, and death. We used LMWH as the main comparator for analysis and performed trial sequential analysis (TSA) for each pairwise comparison. Certainty of evidence was assessed using GRADE (Grading of Recommendations, Assessments, Developments and Evaluations). We analyzed 70 RCTs (55,841 participants). Factor Xa inhibitors decreased postoperative VTE significantly compared with LMWH (odds ratio [OR]: 0.55, 95% confidence interval [CI]: 0.44–0.68, high certainty). Pentasaccharides probably reduce VTE (OR: 0.61, 95% CI: 0.36–1.02, moderate certainty), while the factor IIa inhibitor dabigatran may reduce VTE (OR: 0.75, 95% CI: 0.40–1.42, low certainty). UFH probably increases VTE compared with LMWH (OR: 1.31, 95% CI: 0.91–1.89, moderate certainty), and other agents like warfarin, aspirin, placebo, and usual care without thromboprophylaxis increase VTE (high certainty). Factor Xa inhibitors may not significantly affect major bleeding compared with LMWH (OR: 1.06, 95% CI: 0.81–1.39, low certainty). No medications had a notable effect on

## Keywords

- ▶ meta-analysis
- ▶ total hip or knee arthroplasty
- ▶ venous thromboembolism

\* Contributed equally as first authors.

† Contributed equally as senior authors.

mortality compared with LMWH (very low certainty). TSA suggests sufficient evidence for the benefit of factor Xa inhibitors over LMWH for VTE prevention. Compared with LMWH and aspirin, factor Xa inhibitors are associated with reduced VTE after hip or knee arthroplasty, without an increase in bleeding and likely no impact on mortality.

Following elective total hip or knee arthroplasty (THA or TKA), patients have a higher risk of venous thromboembolism (VTE).<sup>1–4</sup> Symptomatic VTE rates in this setting can be as high as 3% without thromboprophylaxis, and 1.5% with thromboprophylaxis,<sup>4–7</sup> resulting in important morbidity, mortality,<sup>8–10</sup> and health care costs.<sup>11–13</sup> As more arthroplasties are being conducted over time,<sup>14–16</sup> there is a need for appropriate perioperative prophylaxis against thromboembolism informed by best possible evidence summaries.<sup>11,17,18</sup>

Several medications are available for postoperative VTE prophylaxis.<sup>19,20</sup> Various societies have suggested or recommended, with some variation, specific agent(s) for VTE prophylaxis.<sup>19,21–25</sup> Earlier guidelines<sup>24,25</sup> did not specify a recommended agent or duration of therapy, while more recent guidelines have recommended low-dose aspirin (though low-molecular-weight heparin [LMWH] and factor Xa inhibitors had similar efficacy),<sup>26</sup> or LMWH, pentasaccharide, non-vitamin K antagonist oral anticoagulants (NOACs: factor IIa inhibitor dabigatran, factor Xa inhibitors apixaban and rivaroxaban), low-dose unfractionated heparin (UFH), or vitamin K antagonists (VKAs).<sup>23</sup> All guidelines have been limited to weak recommendations and reported very low certainty in the current evidence,<sup>22</sup> highlighting an important knowledge gap.<sup>20</sup>

Prior systematic reviews and meta-analyses have investigated pharmacological thromboprophylaxis in smaller patient populations or intervention groups with unspecified treatment details. While other analyses have found that rivaroxaban was associated with the greatest reduction in deep vein thrombosis (DVT), they were limited by the patient population (only TKAs<sup>27</sup>), or by interventions (comparisons between NOACs and non-NOACs unclear<sup>28</sup>; exclusion of important interventions including aspirin, apixaban, edoxaban<sup>29</sup>). These analyses included a small number of randomized controlled trials (RCTs)<sup>30,31</sup> and included studies which report on doses or regimens of medications which fall outside of current treatment guidelines, which limits the applicability of their results. The aim of this systematic review and network meta-analysis was to summarize the efficacy and safety of pharmacological agents in patients following elective hip and knee arthroplasty.

## Methods

### Search Strategy and Selection Criteria

We registered this study with PROSPERO (CRD42022357206, [https://www.crd.york.ac.uk/prospero/display\\_record.php?RecordID=357206](https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=357206)) and conducted it in adherence with the Preferred Reporting Items for Systematic Reviews and Meta-analyses Statement extension for Network Meta-analysis (► **Supplementary Table S1**).<sup>32</sup> With a medical information specialist, we searched MEDLINE, Embase, and Scopus databases

from inception to 13 October 2023, using the following keywords: “knee arthroplasty” or “hip arthroplasty,” “aspirin” or “heparin” or “direct oral anticoagulant,” “venous thromboembolism” or “hemorrhage,” and “randomized controlled trial” without any limitation for language (► **Supplementary Table S2**). We reviewed the reference lists of included studies and relevant review articles, searched [clinicaltrials.gov](http://clinicaltrials.gov) for unpublished data or protocols, and used an artificial intelligence virtual research assistant (“Elicit”),<sup>33</sup> to obtain any additional studies.

### Eligibility Criteria

We included RCTs comparing two or more medications, or a medication with a control or placebo as venous thromboprophylaxis following elective hip or knee arthroplasty, including LMWH (enoxaparin, dalteparin, nadroparin, and tinzaparin), factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), factor IIa inhibitor (dabigatran), aspirin, UFH, VKAs (warfarin), and pentasaccharide (fondaparinux), as well as placebo and no intervention (control). We excluded trials reporting on hybrid regimens (starting on one medication for a period of time before switching to another medication), animals or pediatric patients (<18 years old), and observational studies. In the case of overlapping patient data, we included the largest study and excluded any other overlapping studies.

### Outcomes

Outcomes included VTE at the longest point of follow-up, bleeding based on the ISTH definition<sup>34</sup> (specifically, major bleeding events), and mortality at the last point of follow-up. If the total number of VTE was reported, we collected that data for analysis. However, if DVT and pulmonary embolism (PE) were reported separately, we combined the number of patients with DVT and PE based on radiological imaging or autopsy.<sup>35</sup>

### Data Collection and Risk-of-Bias Assessment

We collected data using a prespecified data extraction form (► **Supplementary Table S3**). We recorded the event rates and total number of patients in each arm. Where appropriate, we derived the means and standard deviations from the aggregate data presented in each study as per Wan and colleagues.<sup>36</sup>

We assessed individual study risk of bias using the Cochrane Risk of Bias 2.0 tool for RCTs (RoB2.0).<sup>37</sup> We assessed certainty of evidence using the Grading of Recommendations, Assessments, Developments and Evaluations (GRADE) approach, which rates the certainty of evidence from “high” (we are confident that the true effect lies close to that of the estimate of the effect) to “very low” (we have very little confidence in the effect estimate, the true effect is likely to be substantially different from the

estimate of effect).<sup>38,39</sup> We used informative narrative statements to communicate the certainty in the pooled estimates.<sup>40</sup> B.S.J.Y., R.R.L., R.L., and J.W.P. independently and in duplicate conducted two-staged screening of studies (titles and abstracts, followed by full texts), collected data, and assessed risk of bias using the systematic review management software Covidence (Melbourne, Australia); conflicts were resolved by consensus and discussion.

### Data Synthesis

For all comparisons, we first conducted random-effects pairwise meta-analyses. In studies with null events, we applied a continuity correction of 0.5. We present outcomes as pooled odds ratios (ORs) with their corresponding 95% confidence intervals (CIs).

We assessed the feasibility for network meta-analysis by evaluating the availability of evidence, homogeneity of study designs, patients, and characteristics of interventions across the included studies (transitivity), the structural properties of the network (connectivity), and network coherence. We conducted frequentist random-effects network meta-analysis,<sup>41,42</sup> and visualized network geometry using a network graph. We used the thickness and depth of color of each edge to represent the number of studies in each pairwise comparison. We calculated the total network inconsistency based on the full design-by-treatment interaction random-effects model,<sup>43</sup> and assessed incoherence via the node splitting approach. We then estimated the ranking probabilities using the frequentist analogue of the Surface Under the Cumulative Ranking (SUCRA) curve based on 10,000 repetitions.<sup>44</sup>

We conducted several sensitivity analyses: we excluded studies with high risks of bias, combined placebo and control groups under a common node in the network, excluded studies published before 2000 to eliminate the possibility of changes in management over time, separated NOACs into their individual medications (rivaroxaban, apixaban, edoxaban, dabigatran), and stratified aspirin based on dose (low dose  $\leq$  325 mg, high dose  $>$ 325 mg). We also conducted two

subgroup analyses: the first separating the analysis of medications in hip and knee arthroplasties individually, and the second analyses studies that examined prespecified dosing regimens as per package inserts provided by their respective drug manufacturers versus those that did not (► **Table 1**). We tested for interaction between both types of surgery using the ratio of ORs.<sup>45</sup>

We assessed statistical heterogeneity (inconsistency) as part of the GRADE approach, using I-squared, tau-squares values, chi-squared test, and visual inspection of the forest plots.<sup>46</sup> We assessed for publication bias qualitatively using visual inspection of funnel plots. We conducted statistical analysis using R 4.1.2.

In addition, we conducted trial sequential analysis (TSA) for all outcomes to assess each pairwise comparison. The probability of false results increases as more statistical tests are applied to accumulated data.<sup>47</sup> Similar to RCTs, meta-analyses also have a “required information size” to ensure sufficient events and sample size. TSA combines cumulative meta-analysis with information size calculations to estimate the significance of the cumulative pooled estimate following the addition of a new trial,<sup>47</sup> reducing the rates of falsely significant results. We performed TSA using TSA v0.9.5.10 ([www.ctu.dk/tsa](http://www.ctu.dk/tsa)) assuming a type I error of 5% and power of 80%, and used the relative risk reduction, control event proportion, and heterogeneity from each pairwise meta-analysis accordingly.

## Results


Of 2,888 references, we reviewed 229 full texts. We included 70 RCTs (55,841 patients) (► **Fig. 1**).<sup>5,48–116</sup> A total of 22,663 (41.1%) patients were male, and the average age of the patients ranged between 43 and 73 years. In addition, 32,098 (57.7%) of the patients underwent hip arthroplasty while 23,543 (42.3%) of the patients underwent knee arthroplasty. ► **Supplementary Tables S4 to S6** summarize further details of the included studies, and ► **Supplementary Table S7** presents the risk-of-bias judgments of the included studies.

**Table 1** Medication doses for subgroup analysis

Class	Name	Dose
LMWH	Enoxaparin	30 mg SC every 12 hours or 40 mg SC OD
	Dalteparin <sup>a</sup>	2,500 IU SC for first 1 or 2 doses, then 5,000 IU SC OD
	Tinzaparin	50 or 75 IU/kg OD
Anti-Xa	Rivaroxaban	10 mg PO OD
	Apixaban	2.5 mg PO BD
Anti-IIa	Dabigatran <sup>a</sup>	110 mg PO on first day, then 220 mg PO OD
Pentasaccharide	Fondaparinux	2.5 mg SC OD
VKA	Warfarin	Adjusted PO dose to maintain a target INR of 2.5 (INR range: 2.0–3.0)
UFH		5,000 IU SC every 8 or 12 hours
Aspirin		All doses accepted

Abbreviations: BD, twice daily; INR, international normalized ratio; IU, international anti-factor Xa units; LMWH, low-molecular-weight heparin; OD, once daily; PO, per oral; SC, subcutaneous injection; UFH, unfractionated heparin; VKA, vitamin K antagonist.

<sup>a</sup>Approved for total hip arthroplasty only.



**Fig. 1** PRISMA 2020 flow diagram for new systematic reviews which included searches of databases, registers, and other sources.

### Assessment of Study Quality

► **Supplementary Table S7** summarizes the risk of bias of each individual RCTs. We judged three studies to have a high risk of bias (due to bias arising from the randomization process), 18 studies to be at moderate risk of bias (due to deviations from intended interventions and measurement of outcomes), and 49 to be low risk of bias.

### Outcomes

Of 55,841 patients, 4,786 patients (8.6%) had VTE. Compared with LMWH, factor Xa inhibitors reduced VTE (OR: 0.55, 95% CI: 0.44–0.68, high certainty), while pentasaccharide (OR: 0.61, 95% CI: 0.36–1.02, moderate certainty) probably reduced VTE, and the factor IIa inhibitor dabigatran (OR: 0.75, 95% CI: 0.40–1.42) may reduce VTE. On the other hand, compared with LMWH, UFH (OR: 1.31, 95% CI: 0.91–1.89) probably increases VTE (moderate certainty), and warfarin (OR: 1.75, 95% CI: 1.25–2.46), aspirin (OR: 1.91, 95% CI: 1.22–2.99), placebo (OR: 2.35, 95% CI: 1.71–3.24), and usual care without thromboprophylaxis (OR: 3.30, 95% CI: 2.18–4.98) increased VTE (high certainty). ► **Fig. 2** presents the network geometry and ► **Fig. 3** presents the treatment effect of each intervention. ► **Supplementary Figs. S1–S3** represent the direct effect estimates on venous thromboembolism, major bleeding and mortality respectively, in the randomized control trials. ► **Supplementary Fig. S4** presents the network funnel plot and ranking of each intervention based on *p*-scores. ► **Supplementary Table S8** summarizes the GRADE ratings for each comparison.


Based on the sensitivity analysis (► **Supplementary Table S9**), excluding studies rated as high risk of bias, combining both placebo and control arms under a common node (“no intervention”), and excluding studies published before 2000 did not substantially change the pooled estimates, or conclusions.

When separating NOACs into individual medications as separate nodes, we found that compared with LMWH, rivaroxaban (OR: 0.63, 95% CI: 0.47–0.86), edoxaban (OR: 0.42, 95% CI: 0.25–0.68), and apixaban (OR: 0.52, 95% CI: 0.34–0.79) reduced the odds of VTE (all high certainty); while this was still reduced for dabigatran, this was based on low certainty evidence (OR: 0.75, 95% CI: 0.39–1.43). When stratifying aspirin based on dose, compared with LMWH, high-dose aspirin increased VTE (OR: 2.62, 95% CI: 1.31–5.23, high certainty) while low-dose aspirin probably increased VTE (OR: 1.52, 95% CI: 0.85–2.74, moderate certainty). When stratifying studies by the type of operation (hip vs. knee replacement), we did not find any significant interaction effects. Finally, subgroup analysis of 51 studies which used dose-adherent medications did not substantially change the pooled estimates or conclusions. ► **Supplementary Table S9** summarizes the results of the sensitivity and subgroup analyses.


Of 55,462 patients, 586 (1.1%) had a major bleeding event. Compared with LMWH, warfarin (OR: 0.51, 95% CI: 0.33–0.79, moderate certainty) probably decreases major bleeding and placebo (OR: 0.78, 95% CI: 0.45–1.32, low certainty) may reduce bleeding, while it is uncertain if usual care without thromboprophylaxis (OR: 0.66, 95% CI: 0.21–2.15, very low certainty) and aspirin (OR: 0.88, 95% CI: 0.47–1.63, very low certainty) has an effect on major bleeding. On the other hand, again compared with LMWH, pentasaccharide (OR: 1.54, 95% CI: 1.08–2.21, moderate certainty), UFH (OR: 1.60, 95% CI: 0.89–2.86, low certainty), and factor Xa inhibitors (OR: 1.06, 95% CI: 0.81–1.39, low certainty) may increase major bleeding, and it is uncertain if factor IIa inhibitor (OR: 1.53, 95% CI: 0.80–2.91, very low certainty) has an effect on major bleeding.

In total, 88 out of 50,768 (0.17%) patients died. Compared with LMWH, it is uncertain if any of the interventions had an important impact on mortality; these include factor IIa





**Fig. 2** Geometry of the network meta-analysis for venous thromboembolism. The size of each circle (or node) represents the number of studies reporting on each intervention, and the thickness and depth of color of each line (or edge) represents the number of studies comparing between both interventions.



**Fig. 3** Forest plot representing the treatment effect of each intervention compared with low-molecular-weight heparin (the reference group) for venous thromboembolism.

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.

inhibitor (OR: 0.54, 95% CI: 0.09–3.41), placebo (OR: 0.88, 95% CI: 0.23–3.33), factor Xa inhibitors (OR: 1.02, 95% CI: 0.61–1.72), aspirin (OR: 1.07, 95% CI: 0.33–3.45), usual care without thromboprophylaxis (OR: 1.00, 95% CI: 0.06–17.41), warfarin (OR: 1.36, 95% CI: 0.63–2.93), pentasaccharide (OR: 1.31, 95% CI: 0.32–5.37), and UFH (OR: 2.04, 95% CI: 0.54–7.67, all very low certainty). ► **Supplementary Figs. S5 and S6** present the network geometry, treatment effects of each intervention, funnel plot, and ranking of each intervention for major bleeding and death respectively, while ► **Supplementary Tables S10 and S11** summarize the GRADE ratings for major bleeding and death, respectively.

We conducted a TSA for pairwise comparisons of interventions for outcomes of interest (► **Supplementary Tables S12–S14**). Notably, in the comparison of factor Xa inhibitors versus LMWH in preventing VTE, the required information size is attained, and the cumulative Z-curve crosses the boundary for benefit in favor of factor Xa inhibitors. This further supports the conclusion that factor Xa inhibitors are superior to LMWH in preventing VTE. The comparison of aspirin, warfarin, placebo, and control versus LMWH all attained the required information size, and the cumulative Z-curve crosses the boundary for benefit in favor of LMWH.

## Discussion

In this network meta-analysis of 70 RCTs including 55,841 patients, we found, compared with LMWH, that factor Xa inhibitors reduced the odds of VTE without increasing the odds of bleeding or death. Of note, factor IIa inhibitor did not reduce VTE, and warfarin and aspirin increased the odds of VTE, in comparison to LMWH. These results were consistent across several sensitivity and subgroup analyses, which increases the certainty in the findings.

Existing guidelines support pharmacological VTE prophylaxis in elective THA or TKA,<sup>24</sup> though the specific prophylactic strategy varies. Some guidelines recommend LMWH over factor Xa inhibitors,<sup>23</sup> and others recommend NOACs or specifically rivaroxaban.<sup>26</sup> Yet, factor Xa inhibitors, and specifically rivaroxaban, may be associated with increased risks of major bleeding<sup>117–120</sup> when compared with LMWH or apixaban based on a previous network meta-analysis of 19 RCTs.<sup>117</sup> In the current network meta-analysis, factor Xa inhibitors as a group, and individually, were associated with reduced VTE events, but not factor IIa inhibitor. We also did not find an increase in major bleeding when comparing LMWH and factor Xa inhibitors, as well as most other medications. While pentasaccharides are an exception, this is consistent with prior studies.<sup>121</sup> These results support the use of factor Xa inhibitors in reducing VTE post-arthroplasty. In addition, whereas LMWH requires parenteral administration, factor Xa inhibitors can be administered orally, which may be more comfortable for patients and facilitate adherence to outpatient extended thromboprophylaxis.<sup>122</sup>

The role of aspirin as pharmacological thromboprophylaxis remains controversial: while it is recommended for VTE prophylaxis,<sup>22,23</sup> it is unclear if it is preferred over other medications. Although some guidelines recommend low-dose aspirin

as the ideal agent for VTE prophylaxis based on a network meta-analysis of RCTs and observational studies,<sup>26</sup> other guidelines and meta-analyses based on small, low-quality studies found based on low certainty no differences between aspirin and LMWH<sup>123</sup> or other anticoagulants.<sup>22,30</sup> More recent studies suggest that low-dose aspirin was inferior to LMWH, and was associated with a higher risk of VTE than previously reported.<sup>102,116,124,125</sup> In the current network meta-analysis, we found that studies using aspirin as a whole reported higher rates of VTE relative to LMWH. As such, the choice of aspirin as a viable alternative to LMWH should be revisited.

There are several strengths to our study. We combined a network meta-analysis with a TSA, which helped inform the current state of the evidence and literature. In the context of the above, it is unlikely that further trials are required to investigate the efficacy of factor Xa inhibitors as venous thromboprophylaxis in joint arthroplasty. In addition, we conducted subgroup analysis focusing on specific dosing in a real-world context, which aids in transitivity (where indirect estimates accurately mirror an unobserved direct estimate, requiring potential effect modifiers to be similar between studies). The inclusion of other interventions such as pentasaccharide and warfarin increased the sample size and hence, the precision of our analysis. Our analysis is based on a prespecified protocol, and a robust librarian-verified search strategy with comprehensive inclusion criteria. Furthermore, we included unpublished data,<sup>48</sup> which reduces the risk of publication bias. Compared with previous studies,<sup>30,117,123</sup> we included more RCTs and investigated a broader range of medications, which also increases the sample size and hence, precision. We applied the GRADE to communicate findings transparently and efficiently. We adopted more comprehensive and consistent definitions of bleeding,<sup>126</sup> which helps overcome heterogeneity. We stratified the odds of VTE based on individual types of surgery, which is critical in informing future practice for orthopedic surgeons.

However, there are also limitations to this study. First, despite optimizing our inclusion criteria and conducting additional analyses, we detected statistical inconsistency, which may be due to several factors, including changing clinical practices over time, patient demographics and inherent differences in VTE rates across ethnicities,<sup>6</sup> and differences in follow-up durations between studies. Within our study, possible contributors to intransitivity include immobilization,<sup>127</sup> type of anesthesia,<sup>128,129</sup> and co-interventions including mechanical prophylaxis such as graduated compression stockings and intermittent pneumatic compression<sup>130</sup> devices. In addition, in view of the transitivity assumption and lack of randomized data, we could not include studies reporting on hybrid regimens for venous thromboprophylaxis. It is difficult to quantify these interaction effects in the frequentist framework for network meta-analyses, and current software do not allow for covariate adjustment. This is compounded by the fact that these sources of variability were poorly reported and as such, their effect remains unknown. In addition, as a result of applying stricter inclusion criteria to optimize consistency, we reduced the sample size and precision of our analysis. As

such, certain estimates, and the analysis stratified based on the type of surgery, may not be informative due to lack of power rather than a lack of actual differences. There is also a possibility of double counting patients who had both DVT and PE, though this is likely limited to a small subset of patients.<sup>131,132</sup> We were unable to analyze the cost effectiveness of each regimen in view of a paucity of data, though this would also be important to patients and other stakeholders involved. There may be important heterogeneity in the bleeding data as the definitions of major bleeding as a primary safety outcome vary considerably among the RCTs. Studies that excluded surgical-site bleeding from their definition of major bleeding reported major bleeding rates approximately 10 times lower than those studies that included it. In certain RCTs assessing rivaroxaban,<sup>74,97,98,115,116</sup> the definition of major bleeding did not encompass surgical-site bleeding. The majority of trials involving rivaroxaban and apixaban used the hemoglobin level on the first postoperative day as a baseline (to avoid the confounder of intraoperative blood loss) to identify significant drops in hemoglobin as indicative of major bleeding. Moreover, reporting of bleeding was also inconsistent. Some trials reported on the volume of blood transfusion required rather than the number of patients who had a bleeding event; this could not be incorporated into the meta-analysis. Finally, our study population is also not representative of certain patient groups, such as patients with renal impairment or inherited bleeding disorders.

## Conclusion

This frequentist network meta-analysis found that factor Xa inhibitors decrease VTE compared with LMWH and aspirin when used as VTE prophylaxis after elective THA or TKA, without increasing the risk of bleeding or mortality. On the other hand, several agents (aspirin, warfarin) increased the odds of VTE compared with LMWH.

### Conflicts of Interest

R.R.L. receives research support from the Clinician Scientist Development Unit, Yong Loo Lin School of Medicine, Singapore. All other authors declare no competing interests.

### Acknowledgments

The authors would like to acknowledge Swei Nee Wong for her assistance with the search strategy. The authors dedicate this manuscript to Dr. Chuen Seng Tan, who sadly passed away in May 2023.

## References

- Mammen EF. Pathogenesis of venous thrombosis. *Chest* 1992; 102(6, Suppl):640S–644S
- Lie SA, Pratt N, Ryan P, et al. Duration of the increase in early postoperative mortality after elective hip and knee replacement. *J Bone Joint Surg Am* 2010;92(01):58–63
- Keller K, Hobohm L, Barco S, et al. Venous thromboembolism in patients hospitalized for knee and hip joint replacement surgery. *Eur Heart J* 2020;41(02):3567
- Bircher A, Chowdhury A. Current DVT prophylaxis: a review. *Orthop Trauma* 2020;34(03):161–167
- Chin PL, Amin MS, Yang KY, Yeo SJ, Lo NN. Thromboembolic prophylaxis for total knee arthroplasty in Asian patients: a randomised controlled trial. *J Orthop Surg (Hong Kong)* 2009;17(01):1–5
- Loh JLM, Chan S, Wong KL, de Mel S, Yap ES. Chemoprophylaxis in addition to mechanical prophylaxis after total knee arthroplasty surgery does not reduce the incidence of venous thromboembolism. *Thromb J* 2019;17:9
- Warren JA, Sundaram K, Anis HK, Kamath AF, Higuera CA, Piuzei NS. Have venous thromboembolism rates decreased in total hip and knee arthroplasty? *J Arthroplasty* 2020;35(01):259–264
- Lieberman JR, Geerts WH. Prevention of venous thromboembolism after total hip and knee arthroplasty. *J Bone Joint Surg Am* 1994;76(08):1239–1250
- Weitz JI, Bauersachs R, Becker B, et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial. *JAMA* 2020;323(02):130–139
- White RH, Gettner S, Newman JM, Trauner KB, Romano PS. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. *N Engl J Med* 2000;343(24):1758–1764
- Shahi A, Chen AF, Tan TL, Maltenfort MG, Kucukdurmaz F, Parvizi J. The incidence and economic burden of in-hospital venous thromboembolism in the United States. *J Arthroplasty* 2017;32(04):1063–1066
- Santana DC, Emara AK, Orr MN, et al. An update on venous thromboembolism rates and prophylaxis in hip and knee arthroplasty in 2020. *Medicina (Kaunas)* 2020;56(09):416
- Klok FA, van Kralingen KW, van Dijk APJ, et al. Quality of life in long-term survivors of acute pulmonary embolism. *Chest* 2010; 138(06):1432–1440
- Abdelaal MS, Restrepo C, Sharkey PF. Global perspectives on arthroplasty of hip and knee joints. *Orthop Clin North Am* 2020; 51(02):169–176
- Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. *Ann Rheum Dis* 2014;73(07):1323–1330
- Gao J, Xing D, Dong S, Lin J. The primary total knee arthroplasty: a global analysis. *J Orthop Surg Res* 2020;15(01):190
- Fernandez MM, Hogue S, Preblick R, Kwong WJ. Review of the cost of venous thromboembolism. *Clinicoecon Outcomes Res* 2015;7:451–462
- Angchaisuksiri P. Venous thromboembolism in Asia—an unrecognised and under-treated problem? *Thromb Haemost* 2011; 106(04):585–590
- Fleivas DA, Megaloikononimos PD, Dimopoulos L, Mitsiokapa E, Koulouvaris P, Mavrogenis AF. Thromboembolism prophylaxis in orthopaedics: an update. *EFORT Open Rev* 2018;3(04):136–148
- Kahn SR, Shivakumar S. What's new in VTE risk and prevention in orthopedic surgery. *Res Pract Thromb Haemost* 2020;4(03): 366–376
- Afshari A, Ageno W, Ahmed A, et al; ESA VTE Guidelines Task Force. European Guidelines on perioperative venous thromboembolism prophylaxis: executive summary. *Eur J Anaesthesiol* 2018;35(02):77–83
- Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. *Blood Adv* 2019;3(23):3898–3944
- Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2012;141(2, Suppl):e278S–e325S

- 24 Mont MA, Jacobs JJ, Boggio LN, et al; AAOS. Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. *J Am Acad Orthop Surg* 2011;19(12):768–776
- 25 National Institute for Health and Care Excellence. Guidelines. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. London: National Institute for Health and Care Excellence (NICE), Copyright © NICE 2018; 2018
- 26 Mont MA, Abdeen A, Abdel MP, et al; The ICM-VTE Hip & Knee Delegates. Recommendations from the ICM-VTE: hip & knee. *J Bone Joint Surg Am* 2022;104(1, Suppl 1):180–231
- 27 Lewis S, Glen J, Dawoud D, et al. Venous thromboembolism prophylaxis strategies for people undergoing elective total knee replacement: a systematic review and network meta-analysis. *Lancet Haematol* 2019;6(10):e530–e539
- 28 Yi YH, Gong S, Gong TL, Zhou LY, Hu C, Xu WH. New oral anticoagulants for venous thromboembolism prophylaxis in total hip and knee arthroplasty: a systematic review and network meta-analysis. *Front Pharmacol* 2022;12:775126
- 29 Wong SYW, Ler FLS, Sultana R, Bin Abd Razak HR. What is the best prophylaxis against venous thromboembolism in Asians following total knee arthroplasty? A systematic review and network meta-analysis. *Knee Surg Relat Res* 2022;34(01):37
- 30 Matharu GS, Kunutsor SK, Judge A, Blom AW, Whitehouse MR. Clinical effectiveness and safety of aspirin for venous thromboembolism prophylaxis after total hip and knee replacement: a systematic review and meta-analysis of randomized clinical trials. *JAMA Intern Med* 2020;180(03):376–384
- 31 Olukoya O, Fultang J. Aspirin compared with other anticoagulants for use as venous thromboembolism prophylaxis in elective orthopaedic hip and knee operations: a narrative literature review. *Cureus* 2021;13(09):e18249
- 32 Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Int J Surg* 2021;88:105906
- 33 Whitfield S, Hofmann MA. Elicit: AI literature review research assistant. *Public Serv Q* 2023;19(03):201–207
- 34 Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher WSubcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. *J Thromb Haemost* 2010;8(01):202–204
- 35 Wells PS. Integrated strategies for the diagnosis of venous thromboembolism. *J Thromb Haemost* 2007;5(Suppl 1):41–50
- 36 Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol* 2014;14:135
- 37 Sterne J, Savović J, Page M, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019;366:l4898
- 38 Guyatt GH, Thorlund K, Oxman AD, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. *J Clin Epidemiol* 2013;66(02):173–183
- 39 Puhan MA, Schünemann HJ, Murad MH, et al; GRADE Working Group. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. *BMJ* 2014;349:g5630
- 40 Santesso N, Glenton C, Dahm P, et al; GRADE Working Group. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. *J Clin Epidemiol* 2020;119:126–135
- 41 Sturtz S, Bender R. Unsolved issues of mixed treatment comparison meta-analysis: network size and inconsistency. *Res Synth Methods* 2012;3(04):300–311
- 42 Rucker G, Schwarzer G. Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis. *Stat Med* 2014;33(25):4353–4369
- 43 Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. *Res Synth Methods* 2012;3(02):98–110
- 44 Rucker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. *BMC Med Res Methodol* 2015;15(01):58
- 45 Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *BMJ* 2003;326(7382):219
- 46 Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol* 2011;64(04):383–394
- 47 Wetterslev J, Jakobsen JC, Gluud C. Trial sequential analysis in systematic reviews with meta-analysis. *BMC Med Res Methodol* 2017;17(01):39
- 48 Sankyo D. A phase IIb, randomized, parallel group, double-blind, double-dummy, multi-center, multi-national, multi-dose, study of DU-176b compared to dalteparin in patients undergoing elective unilateral total hip replacement. *Natl Inst Allergy Infect Dis* 2018
- 49 The German Hip Arthroplasty Trial (GHAT) Group. Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement. A randomized trial. *Arch Orthop Trauma Surg* 1992;111(02):110–120
- 50 Argun M, Oner M, Saglamoglu M, et al. Fondaparinux versus nadroparin for prevention of venous thromboembolism after elective hip and knee arthroplasty. *Curr Ther Res Clin Exp* 2013;74:49–53
- 51 Eriksson BI, Borris L, Dahl OE, et al; ODIXa-HIP Study Investigators. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. *J Thromb Haemost* 2006;4(01):121–128
- 52 Borris LC, Hauch O, Jorgensen LN, et al; The Danish Enoxaparin Study Group. Low-molecular-weight heparin (enoxaparin) vs dextran 70. The prevention of postoperative deep vein thrombosis after total hip replacement. *Arch Intern Med* 1991;151(08):1621–1624
- 53 Chaudhary D, Singh M, Bhathal M, Baiswar N, Randhawa J, Randhawa D. Role of low molecular weight heparin in thromboprophylaxis for hip and knee arthroplasty. *Indian J Public Health Res Dev* 2019;10(04):174–178
- 54 Colleoni JL, Ribeiro FN, Mos PAC, Reis JP, Oliveira HR, Miura BK. Venous thromboembolism prophylaxis after total knee arthroplasty (TKA): aspirin vs. rivaroxaban. *Rev Bras Ortop* 2017;53(01):22–27
- 55 Colwell CW Jr, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. *J Bone Joint Surg Am* 1999;81(07):932–940
- 56 Colwell CW Jr, Spiro TE, Trowbridge AA, Stephens JWG, Gardiner GA Jr, Ritter MAEnoxaparin Clinical Trial Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. *Clin Orthop Relat Res* 1995;(321):19–27
- 57 Dechavanne M, Ville D, Berruyer M, et al. Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery. *Haemostasis* 1989;19(01):5–12
- 58 Eriksson BI, Borris LC, Dahl OE, et al. Dose-escalation study of rivaroxaban (BAY 59-7939)—an oral, direct Factor Xa inhibitor—for the prevention of venous thromboembolism in patients undergoing total hip replacement. *Thromb Res* 2007;120(05):685–693
- 59 Eriksson BI, Borris LC, Dahl OE, et al; ODIXa-HIP Study Investigators. A once-daily, oral, direct Factor Xa inhibitor,



- rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. *Circulation* 2006;114(22):2374-2381
- 60 Eriksson BI, Borris LC, Friedman RJ, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. *N Engl J Med* 2008;358(26):2765-2775
  - 61 Eriksson BI, Dahl OE, Huo MH, et al; RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II\*). A randomised, double-blind, non-inferiority trial. *Thromb Haemost* 2011;105(04):721-729
  - 62 Eriksson BI, Zachrisson BE, Teger-Nilsson AC, Risberg B. Thrombosis prophylaxis with low molecular weight heparin in total hip replacement. *Br J Surg* 1988;75(11):1053-1057
  - 63 Faunø P, Suomalainen O, Rehnberg V, et al. Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and low-molecular-weight heparin. *J Bone Joint Surg Am* 1994;76(12):1814-1818
  - 64 Fitzgerald RH Jr, Spiro TE, Trowbridge AA, et al; Enoxaparin Clinical Trial Group. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. *J Bone Joint Surg Am* 2001;83(06):900-906
  - 65 Francis CW, Pellegrini VD Jr, Totterman S, et al. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. *J Bone Joint Surg Am* 1997;79(09):1365-1372
  - 66 Fuji T, Fujita S, Ujihira T, Sato T. Dabigatran etexilate prevents venous thromboembolism after total knee arthroplasty in Japanese patients with a safety profile comparable to placebo. *J Arthroplasty* 2010;25(08):1267-1274
  - 67 Fuji T, Fujita S, Tachibana S, Kawai Y. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. *J Thromb Haemost* 2010;8(11):2458-2468
  - 68 Fuji T, Fujita S, Tachibana S, et al. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARSJ-V trial. *Blood* 2010;116(21)
  - 69 Fuji T, Ochi T, Niwa S, Fujita S. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin. *J Orthop Sci* 2008;13(05):442-451
  - 70 Fuji T, Wang CJ, Fujita S, Kawai Y, Kimura T, Tachibana S. Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan. *J Arthroplasty* 2014;29(12):2439-2446
  - 71 Fuji T, Wang CJ, Fujita S, et al. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. *Thromb Res* 2014;134(06):1198-1204
  - 72 Gombár C, Horvath G, Gálity H, Sisák K, Tóth K. Comparison of minor bleeding complications using dabigatran or enoxaparin after cemented total hip arthroplasty. *Arch Orthop Trauma Surg* 2014;134(04):449-457
  - 73 Harris WH, Salzman EW, Athanasoulis CA, Waltman AC, DeSanctis RW. Aspirin prophylaxis of venous thromboembolism after total hip replacement. *N Engl J Med* 1977;297(23):1246-1249
  - 74 Hongnaparak T, Janejaturanon J, Iamthanaporn K, Tanutit P, Yuenyongviwat V. Aspirin versus rivaroxaban to prevent venous thromboembolism after total knee arthroplasty: a double-blinded, randomized controlled trial. *Rev Bras Ortop* 2021;57(05):741-746
  - 75 Hull RD, Pineo GF, Francis C, et al; North American Fragmin Trial Investigators. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. *Arch Intern Med* 2000;160(14):2208-2215
  - 76 Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. *Arch Intern Med* 1997;157(03):298-303
  - 77 Intiyanaravut T, Thongpulsawasdi N, Sinthuvanich N, Teavirat S, Kunopart M. Enoxaparin versus no anticoagulation prophylaxis after total knee arthroplasty in Thai patients: a randomized controlled trial. *J Med Assoc Thai* 2017;100(01):42-49
  - 78 Jiang H, Meng J, Guo T, et al. Comparison of apixaban and low molecular weight heparin in preventing deep venous thrombosis after total knee arthroplasty in older adults. *Yonsei Med J* 2019;60(07):626-632
  - 79 Kakkar AK, Brenner B, Dahl OE, et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. *Lancet* 2008;372(9632):31-39
  - 80 Kalodiki EP, Hoppensteadt DA, Nicolaides AN, et al. Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial. *Int Angiol* 1996;15(02):162-168
  - 81 Kim SM, Moon YW, Lim SJ, Kim DW, Park YS. Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty. *Thromb Haemost* 2016;115(03):600-607
  - 82 Kim YH, Choi IY, Park MR, Park TS, Cho JL. Prophylaxis for deep vein thrombosis with aspirin or low molecular weight dextran in Korean patients undergoing total hip replacement. A randomized controlled trial. *Int Orthop* 1998;22(01):6-10
  - 83 Lassen MR, Ageno W, Borris LC, et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. *N Engl J Med* 2008;358(26):2776-2786
  - 84 Lassen MR, Bauer KA, Eriksson BI, Turpie AGEuropean Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. *Lancet* 2002;359(9319):1715-1720
  - 85 Lassen MR, Borris LC, Christiansen HM, et al. Prevention of thromboembolism in 190 hip arthroplasties. Comparison of LMW heparin and placebo. *Acta Orthop Scand* 1991;62(01):33-38
  - 86 Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. *J Thromb Haemost* 2007;5(12):2368-2375
  - 87 Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LMADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. *N Engl J Med* 2010;363(26):2487-2498
  - 88 Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick PADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. *Lancet* 2010;375(9717):807-815
  - 89 Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. *N Engl J Med* 2009;361(06):594-604
  - 90 Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of deep vein thrombosis after major knee surgery—a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. *Thromb Haemost* 1992;67(04):417-423
  - 91 Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. *Ann Intern Med* 1996;124(07):619-626

- 92 Leyvraz PF, Bachmann F, Hoek J, et al. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. *BMJ* 1991;303(6802):543–548
- 93 Mätzsch T, Bergqvist D, Fredin H, Hedner U. Low molecular weight heparin compared with dextran as prophylaxis against thrombosis after total hip replacement. *Acta Chir Scand* 1990; 156(6–7):445–450
- 94 Menzin J, Richner R, Huse D, Colditz GA, Oster G. Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluation. *Ann Pharmacother* 1994;28(02):271–275
- 95 Mirdamadi A, Dashtkar S, Kaji M, Pazhang F, Haghpanah B, Gharipour M. Dabigatran versus Enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized clinical trial. *ARYA Atheroscler* 2014;10(06): 292–297
- 96 Planes A, Vochelle N, Mazas F, et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. *Thromb Haemost* 1988;60 (03):407–410
- 97 Rahman WA, Habsa GH, Al-Mohrej OA, Hammad M, Selim NM, Hammad A. Incidence of silent venous thromboembolism after total hip arthroplasty: a comparison of rivaroxaban and enoxaparin. *J Orthop Surg (Hong Kong)* 2020;28(02):2309499020938865
- 98 Ren Y, Cao SL, Li Z, Luo T, Feng B, Weng XS. Comparable efficacy of 100 mg aspirin twice daily and rivaroxaban for venous thromboembolism prophylaxis following primary total hip arthroplasty: a randomized controlled trial. *Chin Med J (Engl)* 2021; 134(02):164–172
- 99 Samama CM, Clergue F, Barre J, Montefiore A, III P, Samii K Arar Study Group. Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery. *Br J Anaesth* 1997;78(06):660–665
- 100 Schöndorf TH, Hey D. Modified “low-dose” heparin prophylaxis to reduce thrombosis after hip joint operations. *Thromb Res* 1978;12(01):153–163
- 101 Senaran H, Acaroğlu E, Ozdemir HM, Atila B. Enoxaparin and heparin comparison of deep vein thrombosis prophylaxis in total hip replacement patients. *Arch Orthop Trauma Surg* 2006;126 (01):1–5
- 102 Sidhu VS, Kelly T-L, Pratt N, et al; CRISTAL Study Group. Effect of aspirin vs enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: the CRISTAL randomized trial. *JAMA* 2022;328(08):719–727
- 103 Sueta D, Kaikita K, Okamoto N, et al; ESCORT-TKA Study Investigators. Edoxaban enhances thromboprophylaxis by physiotherapy after total knee arthroplasty: the randomized controlled escort-tka trial. *Circ J* 2018;82(02):524–531
- 104 Tørholm C, Broeng L, Jørgensen PS, et al. Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. A placebo controlled study. *J Bone Joint Surg Br* 1991;73(03):434–438
- 105 Turpie AG, Bauer KA, Eriksson BI, Lassen MR PENTATHALON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. *Lancet* 2002;359(9319):1721–1726
- 106 Turpie AG, Fisher WD, Bauer KA, et al; OdiXa-Knee Study Group. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. *J Thromb Haemost* 2005;3(11):2479–2486
- 107 Turpie AG, Gallus AS, Hoek J APentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. *N Engl J Med* 2001; 344(09):619–625
- 108 Turpie AG, Lassen MR, Davidson BL, et al; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. *Lancet* 2009;373(9676):1673–1680
- 109 Turpie AG, Levine MN, Hirsh J, et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. *N Engl J Med* 1986;315(15):925–929
- 110 Wang CJ, Wang JW, Weng LH, Hsu CC, Huang CC, Yu PC. Prevention of deep-vein thrombosis after total knee arthroplasty in Asian patients. Comparison of low-molecular-weight heparin and indomethacin. *J Bone Joint Surg Am* 2004;86(01):136–140
- 111 Woolson ST, Watt JM. Intermittent pneumatic compression to prevent proximal deep venous thrombosis during and after total hip replacement. A prospective, randomized study of compression alone, compression and aspirin, and compression and low-dose warfarin. *J Bone Joint Surg Am* 1991;73(04):507–512
- 112 Xie J, Ma J, Huang Q, Yue C, Pei F. Comparison of enoxaparin and rivaroxaban in balance of anti-fibrinolysis and anticoagulation following primary total knee replacement: a pilot study. *Med Sci Monit* 2017;23:704–711
- 113 Yokote R, Matsubara M, Hirasawa N, Hagio S, Ishii K, Takata C. Is routine chemical thromboprophylaxis after total hip replacement really necessary in a Japanese population? *J Bone Joint Surg Br* 2011;93(02):251–256
- 114 Yoo MC, Kang CS, Kim YH, Kim SK. A prospective randomized study on the use of nadroparin calcium in the prophylaxis of thromboembolism in Korean patients undergoing elective total hip replacement. *Int Orthop* 1997;21(06):399–402
- 115 Zhang YM, Liu JY, Sun XD, Zhang M, Liu XG, Chen XL. Rivaroxaban improves hidden blood loss, blood transfusion rate and reduces swelling of the knee joint in knee osteoarthritis patients after total knee replacement. *Medicine (Baltimore)* 2018;97(40): e12630
- 116 Zou Y, Tian S, Wang Y, Sun K. Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty. *Blood Coagul Fibrinolysis* 2014;25(07):660–664
- 117 Hur M, Park S-K, Koo C-H, et al. Comparative efficacy and safety of anticoagulants for prevention of venous thromboembolism after hip and knee arthroplasty. *Acta Orthop* 2017;88(06):634–641
- 118 Gómez-Outes A, Terleira-Fernández AI, Suárez-Gea ML, Vargas-Castrillón E. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. *BMJ* 2012;344:e3675
- 119 Feng W, Wu K, Liu Z, et al. Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis. *Thromb Res* 2015;136(06):1133–1144
- 120 Jameson SS, Rymaszewska M, Hui AC, James P, Serrano-Pedraza I, Muller SD. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty. *J Bone Joint Surg Am* 2012;94(17):1554–1558
- 121 Dong K, Song Y, Li X, et al. Pentasaccharides for the prevention of venous thromboembolism. *Cochrane Database Syst Rev* 2016;10 (10):CD005134
- 122 Peidro-Garcés L, Otero-Fernandez R, Lozano-Lizarraga L. Adherence to and satisfaction with oral outpatient thromboembolism prophylaxis compared to parenteral: SALTO study [in Spanish]. *Rev Esp Cir Ortop Traumatol* 2013;57(01):53–60
- 123 Kapoor A, Ellis A, Shaffer N, et al. Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: a network meta-analysis. *J Thromb Haemost* 2017;15(02):284–294

- 124 Haac BE, O'Hara NN, Manson TT, et al; ADAPT Investigators. Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: a patient-centered randomized controlled trial. *PLoS One* 2020; 15(08):e0235628
- 125 Sharda AV, Fatovic K, Bauer KA. Aspirin thromboprophylaxis in joint replacement surgery. *Res Pract Thromb Haemost* 2022;6(01):e12649
- 126 Kaatz S, Ahmad D, Spyropoulos AC, Schulman S Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. *J Thromb Haemost* 2015;13(11):2119–2126
- 127 Kang BJ, Lee Y-K, Kim HJ, Ha Y-C, Koo K-H. Deep venous thrombosis and pulmonary embolism are uncommon in East Asian patients after total hip arthroplasty. *Clin Orthop Relat Res* 2011;469(12):3423–3428
- 128 Jaffer AK, Barsoum WK, Krebs V, Hurbanek JG, Morra N, Brotman DJ. Duration of anesthesia and venous thromboembolism after hip and knee arthroplasty. *Mayo Clin Proc* 2005;80(06):732–738
- 129 Nakamura M, Kamei M, Bito S, et al. Spinal anesthesia increases the risk of venous thromboembolism in total arthroplasty: secondary analysis of a J-PSVT cohort study on anesthesia. *Medicine (Baltimore)* 2017;96(18):e6748
- 130 Pavon JM, Adam SS, Razouki ZA, et al. Effectiveness of intermittent pneumatic compression devices for venous thromboembolism prophylaxis in high-risk surgical patients: a systematic review. *J Arthroplasty* 2016;31(02):524–532
- 131 Lee SY, Ro H, Chung CY, et al. Incidence of deep vein thrombosis after major lower limb orthopedic surgery: analysis of a nationwide claim registry. *Yonsei Med J* 2015;56(01):139–145
- 132 Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126(3, Suppl):338S–400S